A retrospective cohort Single center study comparing the serologic responses of monoclonal antibody treated and untreated COVID-19 patients at high risk for severe outcome
Latest Information Update: 30 Mar 2022
At a glance
- Drugs Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary) ; Etesevimab (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 30 Mar 2022 New trial record
- 01 Mar 2022 Results published in the Clinical Immunology